<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00519155</url>
  </required_header>
  <id_info>
    <org_study_id>Scil-MD05-C02</org_study_id>
    <secondary_id>EudraCT-No.: 2006-005883-25</secondary_id>
    <nct_id>NCT00519155</nct_id>
  </id_info>
  <brief_title>Pilot Study on MD05 in Comparison With Open Flap Debridement in Patients Undergoing Periodontal Surgery</brief_title>
  <official_title>Pilot Study on Safety and Explorative Efficacy of MD05 in Comparison With Open Flap Debridement in Patients Undergoing Periodontal Surgery to Treat Deep Intrabony Defects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scil Technology GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FGK Clinical Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Scil Technology GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to gain experience of safety and efficacy with MD05 in man in&#xD;
      alveolar bone regeneration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">November 2008</completion_date>
  <primary_completion_date type="Anticipated">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of regeneration of alveolar bone.</measure>
    <time_frame>October 2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evidence of uncompromised healing.</measure>
    <time_frame>October 2008</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Alveolar Bone Loss</condition>
  <condition>Periodontal Bone Loss</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open flap debridement + MD05</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open flap debridement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MD05 and open flap debridement</intervention_name>
    <description>recombinant human GDF-5 coated onto ß-tricalcium phosphate</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open flap debridement</intervention_name>
    <description>Open flap debridement alone</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients requiring extraction of teeth with advanced intrabony periodontal defects at&#xD;
             single rooted teeth without root concavities/furrows located in the maxilla and&#xD;
             mandible (maxillary/mandibular premolars, maxillary incisors; presurgery probing depth&#xD;
             ≥ 6 mm, intrasurgery defect depth ≥ 4 mm) or located the mesial or distal aspect of&#xD;
             mandibular molar teeth without adjacent teeth (excluding defects also involving the&#xD;
             furcation area).&#xD;
&#xD;
          -  Teeth to be treated must be scheduled for extraction in a treatment plan established&#xD;
             by clinicians unrelated to the study.&#xD;
&#xD;
          -  Male and female patients, aged 18 - 75 years&#xD;
&#xD;
          -  Patients must be non-smokers&#xD;
&#xD;
          -  Female patients must be infertile (either sterilized or postmenopausal). If a&#xD;
             patient's menopausal status at screening is uncertain, levels of follicle stimulating&#xD;
             hormone (FSH) should be determined. Patients with an FSH level &gt; 25 IU/l and absence&#xD;
             of menstrual bleeding &gt; 6 months will satisfy the definition of postmenopausal status.&#xD;
&#xD;
          -  Patient must provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of childbearing potential, pregnant or lactating women&#xD;
&#xD;
          -  Participation in another clinical study within 30 days prior to study start&#xD;
&#xD;
          -  Previous participation in this study&#xD;
&#xD;
          -  Legal incompetence or restricted legal competence&#xD;
&#xD;
          -  Alcoholism, drug dependency, smoking&#xD;
&#xD;
          -  Acute or chronic infection at the application site&#xD;
&#xD;
          -  Known infection with HIV, HBV, or HCV&#xD;
&#xD;
          -  Severe allergic rhinitis which requires permanent medication&#xD;
&#xD;
          -  Known intolerance of or hypersensitivity to ß-TCP or rhGDF?5&#xD;
&#xD;
          -  Presence of local or systemic malignant disease or history of local or systemic&#xD;
             malignant disease in the past 5 years.&#xD;
&#xD;
          -  Patients requiring chemo- or radiotherapy&#xD;
&#xD;
          -  Previous or current radiotherapy of the head&#xD;
&#xD;
          -  Chronic liver disorder (AST and/or ALT over 2 times upper limit of normal)&#xD;
&#xD;
          -  Impaired renal function (creatinine over 1.5 times upper limit of normal)&#xD;
&#xD;
          -  Uncontrolled insulin-dependent diabetes mellitus (HbA1c &gt; 7%)&#xD;
&#xD;
          -  Clinically relevant symptoms of thyroid dysfunction&#xD;
&#xD;
          -  Severe hypertension (RRdiast &gt; 110 mmHg)&#xD;
&#xD;
          -  Clinically relevant cardiovascular disease e.g., decompensated cardiac insufficiency,&#xD;
             hemodynamically relevant heart valve defects, or myocardial infarction during the last&#xD;
             three months&#xD;
&#xD;
          -  Systemic bone disease or illness having influence in bone metabolism (e.g.&#xD;
             Osteogenesis imperfecta, Paget's disease, Ehlers-Danlos disease, osteomalacia, renal&#xD;
             osteodystrophia, hyperparathyroidism)&#xD;
&#xD;
          -  Clinically relevant blood coagulation disorder&#xD;
&#xD;
          -  Leukopenia &lt; 3.500 leukocytes/µL&#xD;
&#xD;
          -  Previous (within last 2 months before screening visit) or current treatment with&#xD;
             systemic corticosteroids of more than 5 mg/day prednisone equivalent&#xD;
&#xD;
          -  Previous or current therapy with drugs having any influence on bone metabolism such as&#xD;
             calcitonin or parathormone (as teriparatid) within the last 6 months before screening&#xD;
             visit, bisphosphonates or fluoride at least for 30 days within the last 12 months&#xD;
             before screening visit&#xD;
&#xD;
          -  Previous (within last 2 months before screening visit) or current treatment with&#xD;
             immunosuppressant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anton Sculean, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Periodontology; Radboud University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Periodontology, Semmelweis University Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>August 21, 2007</study_first_submitted>
  <study_first_submitted_qc>August 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2007</study_first_posted>
  <last_update_submitted>April 21, 2008</last_update_submitted>
  <last_update_submitted_qc>April 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>Björn Capsius</name_title>
    <organization>Scil Technology GmbH</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alveolar Bone Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

